Company intelligence / Profile preview
NewAmsterdam Pharma
Naarden, Netherlandsnewamsterdampharma.com ↗
- Ownership
- Public · NAMS
- Employees
- ~68
- Development stage
- Phase 3
01
Overview
Positive Phase 3 results from multiple trials: BROOKLYN showed 41.5% LDL-C reduction at one year in HeFH patients; BROADWAY demonstrated 33% LDL-C reduction and 21% MACE reduction; TANDEM (fixed-dose combination with ezetimibe) achieved 49% LDL-C reduction[8][9]
- Therapeutic areas
- CardiovascularNeurologyMetabolic Disorders
- Modalities
- Small molecules (CETP inhibitors)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Menarini Group (European commercialization partnership)
04
Financials
- Market cap
- $3B
- Total revenue
- $3.7M
- Enterprise value
- $2.4B
Beyond the preview
Go deeper on NewAmsterdam Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NewAmsterdam Pharma.